← Leaderboards
David B. Weiner
Wistar Institute
$32,577,386
Attributed
$32,577,386
Total exposure
19
Grants
18
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $6.7M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$78,749,724 · 24
By mechanism
U19$40,983,728 · 8
P01$23,433,470 · 9
R01$10,884,196 · 3
U01$2,498,274 · 1
T32$938,056 · 1
R13$12,000 · 2
Top collaborators
- Daniel Kulp1 shared
- Jesper Pallesen1 shared
Others in their field
Top investigators on “Vaccines”
- Lawrence Corey · Fred Hutchinson Cancer Center$829,044,908
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$556,540,832
- Bambra Strokes · Ppd Development Lp$526,656,217
- Barton F Haynes · Duke University$515,215,260
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$398,445,678
- Dennis R. Burton · Scripps Research Institute$316,106,418
Research focus
VaccinesProgramsAntigensImmuneAdjuvantSynthetic ConstructImmune ResponseResponseT-LymphocyteDna VaccinesImmunityPlasmidsImmunizationDesignHiv VaccineVaccine DevelopmentCytokineAnimalsInnovationClinicIn VivoTechnologyImmunogenicityVaccination
Grant awards (79)
Synthetic DNA-launched and adjuvanted Env immunogens for HIV$2,424,072
U19 · FY2025 · AI · contact PI
Design and optimization of DL-NLTs and molecular adjuvants to increase potency and promote NAb formation in vivo$924,582
U19 · FY2025 · AI · contact PI
Structural vaccinology guided development of a universal CoV vaccine utilizing nucleic acid delivered nanoparticles$890,878
P01 · FY2025 · AI · contact PI
Administrative Core$697,854
U19 · FY2025 · AI · contact PI
Rapid, single-dose coronavirus vaccines via DNA-launched nanoparticles and genetic adjuvants for durable anti-coronavirus immunity$497,477
P01 · FY2025 · AI · contact PI
Administrative Core$107,473
P01 · FY2025 · AI · contact PI
Synthetic DNA-launched and adjuvanted Env immunogens for HIV$4,420,687
U19 · FY2024 · AI · contact PI
Design and optimization of DL-NLTs and molecular adjuvants to increase potency and promote NAb formation in vivo$1,327,040
U19 · FY2024 · AI · contact PI
Administrative Core$740,051
U19 · FY2024 · AI · contact PI
ISV - International Society for Vaccines 2024 Annual Congress$7,000
R13 · FY2024 · AI · contact PI
Synthetic DNA-launched and adjuvanted Env immunogens for HIV$4,497,948
U19 · FY2023 · AI · contact PI
Design and optimization of DL-NLTs and molecular adjuvants to increase potency and promote NAb formation in vivo$1,427,603
U19 · FY2023 · AI · contact PI
Administrative Core$726,886
U19 · FY2023 · AI · contact PI
2023 International Society for Vaccines (ISV) Annual Congress, October 22-25, Lausanne, Switzerland$5,000
R13 · FY2023 · AI · contact PI
Structural vaccinology guided development of a universal CoV vaccine utilizing nucleic acid delivered nanoparticles$2,626,814
P01 · FY2022 · AI · contact PI
Rapid, single-dose coronavirus vaccines via DNA-launched nanoparticles and genetic adjuvants for durable anti-coronavirus immunity$1,107,120
P01 · FY2022 · AI · contact PI
Novel DNA encoded monoclonal antibodies (DMAbs) for control of Antimicrobial Resistant (AMR) Pseudomonas aeruginosa infection$979,174
R01 · FY2022 · AI · contact PI
Multivalent DNA vaccine-mediated protection against Tuberculosis$865,253
R01 · FY2022 · AI · contact PI
Administrative Core$275,223
P01 · FY2022 · AI · contact PI
Novel DNA encoded monoclonal antibodies (DMAbs) for control of Antimicrobial Resistant (AMR) Pseudomonas aeruginosa infection$950,616
R01 · FY2021 · AI · contact PI
Multivalent DNA vaccine-mediated protection against Tuberculosis$908,439
R01 · FY2021 · AI · contact PI
Novel DNA encoded monoclonal antibodies (DMAbs) for control of Antimicrobial Resistant (AMR) Pseudomonas aeruginosa infection$1,153,277
R01 · FY2020 · AI · contact PI
Multivalent DNA vaccine-mediated protection against Tuberculosis$405,607
R01 · FY2020 · AI · contact PI
Synthetic DNA & Novel Env Vaccine for HIV$3,351,099
U19 · FY2019 · AI · contact PI
Novel DNA encoded monoclonal antibodies (DMAbs) for control of Antimicrobial Resistant (AMR) Pseudomonas aeruginosa infection$1,541,486
R01 · FY2019 · AI · contact PI
Cellular Responses$742,677
U19 · FY2019 · AI · contact PI
Multivalent DNA vaccine-mediated protection against Tuberculosis$370,420
R01 · FY2019 · AI · contact PI
Administration$240,305
U19 · FY2019 · AI · contact PI
Synthetic DNA & Novel Env Vaccine for HIV$3,340,504
U19 · FY2018 · AI · contact PI
Cellular Responses$1,093,465
U19 · FY2018 · AI · contact PI
Multivalent DNA vaccine-mediated protection against Tuberculosis$675,566
R01 · FY2018 · AI · contact PI
Administration$258,908
U19 · FY2018 · AI · contact PI
Synthetic DNA & Novel Env Vaccine for HIV$3,337,497
U19 · FY2017 · AI · contact PI
Cellular Responses$656,708
U19 · FY2017 · AI · contact PI
Administration$213,918
U19 · FY2017 · AI · contact PI
Synthetic DNA & Novel Env Vaccine for HIV$3,424,516
U19 · FY2016 · AI · contact PI
Cellular Responses$732,854
U19 · FY2016 · AI · contact PI
Administration$152,998
U19 · FY2016 · AI · contact PI
Synthetic DNA & Novel Env Vaccine for HIV$3,200,000
U19 · FY2015 · AI · contact PI
Cellular Responses$624,486
U19 · FY2015 · AI · contact PI
Administration$197,316
U19 · FY2015 · AI · contact PI
Development of a Universal Influenza Seasonal Vaccine$360,779
R01 · FY2014 · AI · contact PI
Development of a Universal Influenza Seasonal Vaccine$107,524
R01 · FY2014 · AI · contact PI
Development of a Universal Influenza Seasonal Vaccine$547,964
R01 · FY2013 · AI · contact PI
DNA Vaccine for Induction of Mucosal Immunity$220,546
P01 · FY2013 · AI · contact PI
Development of a Universal Influenza Seasonal Vaccine$1,113,078
R01 · FY2012 · AI · contact PI
Training in Vaccine & Immune Therapeutics$197,623
T32 · FY2012 · AI · contact PI
DNA Vaccine for Induction of Mucosal Immunity$2,898,353
P01 · FY2011 · AI · contact PI
DNA Vaccine for Induction of Mucosal Immunity$889,109
P01 · FY2011 · AI · contact PI
Development of a Universal Influenza Seasonal Vaccine$428,533
R01 · FY2011 · AI · contact PI
Training in Vaccine & Immune Therapeutics$160,215
T32 · FY2011 · AI · contact PI
DNA Vaccine for Induction of Mucosal Immunity$1,888,163
P01 · FY2010 · AI · contact PI
DNA Vaccine for Induction of Mucosal Immunity$539,962
P01 · FY2010 · AI · contact PI
Development of a Universal Influenza Seasonal Vaccine$476,480
R01 · FY2010 · AI · contact PI
Training in Vaccine & Immune Therapeutics$190,888
T32 · FY2010 · AI · contact PI
DNA Vaccine for Induction of Mucosal Immunity$1,767,044
P01 · FY2009 · AI · contact PI
DNA Vaccine for Induction of Mucosal Immunity$534,596
P01 · FY2009 · AI · contact PI
Active Immune Therapy and HAART for HIV-1 Infection$313,601
U19 · FY2009 · AI · contact PI
Training in Vaccine & Immune Therapeutics$195,216
T32 · FY2009 · AI · contact PI
DNA Vaccine for Induction of Mucosal Immunity$1,569,914
P01 · FY2008 · AI · contact PI
DNA Vaccine for Induction of Mucosal Immunity$480,105
P01 · FY2008 · AI · contact PI
Active Immune Therapy and HAART for HIV-1 Infection$320,007
U19 · FY2008 · AI · contact PI
Training in Vaccine & Immune Therapeutics$194,114
T32 · FY2008 · AI · contact PI
Administrative Core$168,098
P01 · FY2008 · AI · contact PI
DNA Vaccine for Induction of Mucosal Immunity$1,748,222
P01 · FY2007 · AI · contact PI
Novel Vaccines for Smallpox$504,171
U01 · FY2007 · AI · contact PI
DNA Vaccine for Induction of Mucosal Immunity$474,130
P01 · FY2007 · AI · contact PI
Administration & Oversight$184,162
P01 · FY2007 · AI · contact PI
Novel Vaccines for Smallpox$508,965
U01 · FY2006 · AI · contact PI
Novel Vaccines for Smallpox$492,742
U01 · FY2005 · AI
Novel Vaccines for Smallpox$46,789
U01 · FY2005 · AI
Active Immune Therapy and HAART for HIV-1 Infection$1,596,146
U19 · FY2004 · AI
Novel Vaccines for Smallpox$474,345
U01 · FY2004 · AI
Active Immune Therapy and HAART for HIV-1 Infection$1,549,799
P01 · FY2003 · AI
Novel Vaccines for Smallpox$471,262
U01 · FY2003 · AI
Active Immune Therapy and HAART for HIV-1 Infection$1,625,574
P01 · FY2002 · AI
IMMUNOPATHOGENESIS$0
P01 · FY2002 · AI
Active Immune Therapy and HAART for HIV-1 Infection$1,390,708
P01 · FY2001 · AI
IMMUNOPATHOGENESIS$0
P01 · FY2001 · AI